The 14-3-3 protein family is a group of conserved regulatory molecules expressed in all eukaryotic cells. In the context of neurodegenerative diseases, 14-3-3 proteins in cerebrospinal fluid (CSF) serve as important biomarkers for prion diseases and other conditions involving rapid neuronal damage. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | CSF Biomarker | [4]
| Target | 14-3-3 Proteins (β, ε, γ, η, σ, θ, ζ isoforms) | [5]
| Sample Type | Cerebrospinal Fluid | [6]
| Diseases | Creutzfeldt-Jakob Disease, Rapidly Progressive Dementia, ALS | [7]
| Sensitivity | 80-95% for CJD |
| Specificity | 85-95% for CJD vs. other dementias |
The 14-3-3 family consists of seven isoforms (β, ε, γ, η, σ, θ, ζ) that function as adapter proteins involved in signal transduction, cell cycle regulation, and apoptosis. These proteins are abundant in neuronal tissue and are released into CSF following neuronal injury or death.
The detection of 14-3-3 proteins in CSF is a well-established diagnostic marker for sporadic CJD and other prion diseases. The test is included in the WHO diagnostic criteria for CJD.
14-3-3 CSF levels can help differentiate:
| Condition | 14-3-3 Status |
|---|---|
| Sporadic CJD | Typically Positive |
| Variant CJD | Usually Positive |
| Familial CJD | Usually Positive |
| FFI | Variable |
| Alzheimer's Disease | Usually Negative |
| Lewy Body Dementia | Usually Negative |
| Vascular Dementia | Usually Negative |
| Autoimmune Encephalitis | May be Positive |
Elevated 14-3-3 in CSF has been reported in:
The 14-3-3 protein detection in CSF relies on highly sensitive immunological techniques. Three primary methodologies have been established in clinical and research settings:
Western Blot (Immunoblot): The gold standard method for 14-3-3 protein detection. This technique separates proteins by molecular weight and uses specific antibodies to detect 14-3-3 isoforms (β, ε, η, γ, ζ, σ, θ)[8]. Western blot provides high specificity and can distinguish between different 14-3-3 isoforms, which may have diagnostic relevance[1:1]. The technique requires approximately 50-100 μL of CSF and has a turnaround time of 24-48 hours.
Enzyme-Linked Immunosorbent Assay (ELISA): A quantitative approach that measures 14-3-3 protein concentrations through antibody-antigen interactions[2:1]. ELISA offers advantages in throughput and objectivity compared to Western blot. Commercial ELISA kits have been validated for CJD screening with reported sensitivities of 85-95% and specificities of 80-95%[3:1]. However, ELISA may miss samples with low 14-3-3 levels that Western blot can detect.
Immunoprecipitation followed by Mass Spectrometry: An advanced technique used in research settings to identify specific 14-3-3 isoforms and post-translational modifications[4:1]. This method provides the highest specificity but requires specialized equipment and expertise.
Proper CSF sample collection and handling are critical for accurate 14-3-3 protein detection. Preanalytical variables significantly impact test sensitivity and specificity.
Collection Procedure:
Storage Requirements:
Quality Indicators:
Transportation:
Interpretation of 14-3-3 protein results requires integration with clinical findings. The following guidelines help ensure accurate result interpretation:
Result Categories:
| 14-3-3 Result | Interpretation | Clinical Correlation |
|---|---|---|
| Strong Positive | High likelihood of prion disease (sensitivity ~95% in sporadic CJD) | Correlate with rapid progressive dementia, myoclonus, ataxia |
| Weak Positive | Possible prion disease, recommend repeat testing | Consider atypical presentations, focal variants |
| Negative | Does not rule out prion disease (sensitivity ~85%) | Clinical suspicion may warrant repeat LP or alternative tests |
Factors Affecting Interpretation:
Clinical Decision Algorithm:
Limitations:
Emerging research focuses on:
Isoform-specific detection: Distinguishing which 14-3-3 isoforms are present
Combination biomarkers: Using 14-3-3 with tau, NfL), or other markers
Real-time quaking-induced conversion (RT-QuIC): More specific prion detection
Automated detection methods: Improving assay standardization
Creutzfeldt-Jakob Disease
CSF Biomarkers
Neurofilament Light Chain
Prion Disease Treatment
Rapidly Progressive Dementia
Cuadrado-Corrales N, et al. The impact of 14-3-3 testing on the diagnosis of Creutzfeldt-Jakob disease (2010). Clin Vaccine Immunol. 2010. ↩︎ ↩︎ ↩︎ ↩︎
Choe LH, et al. 14-3-3 proteins in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease (2012). Neurosci Lett. 2012. ↩︎ ↩︎ ↩︎ ↩︎
Collins SJ, et al. Diagnostic utility of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease (2006). Neurology. 2006. ↩︎ ↩︎ ↩︎ ↩︎
van Dellen E, et al. 14-3-3 proteins in cerebrospinal fluid as biomarkers for ALS (2018). J Neurol Neurosurg Psychiatry. 2018. ↩︎ ↩︎
Geschwind MD, et al. 14-3-3 protein in the CSF is not a useful biomarker for sporadic CJD (2013). Ann Neurol. 2013. ↩︎
Muayqil T, et al. A systematic review and meta-analysis of CSF 14-3-3 as a diagnostic marker for Creutzfeldt-Jakob disease (2012). PLoS One. 2012. ↩︎
Llorens F, et al. 14-3-3 protein isoforms and their implications in prion disease (2018). Brain Pathol. 2018. ↩︎
Zerr I, et al. Assessment of 14-3-3 and tau proteins in CSF for differential diagnosis of prion disease (2000). Lancet. 2000. ↩︎ ↩︎ ↩︎